Forge Biologics is a gene therapy development engine, focused on enabling access to life changing gene
therapies. Forge aims to bring a patients-first approach to accelerate transformative medicines for those
who need them most and is building capacity to address the growing demand for gene therapy
manufacturing. Through its state-of-the-art, 175,000 ft2 cGMP facility, dedicated to AAV viral vector
production, Forge offers end-to-end capabilities to accelerate gene therapy programs from preclinical stage
through clinical, and on to commercial-scale production. With this facility as its foundation, Forge is
developing a proprietary pipeline of disease-modifying AAV-based therapies to potentially help patients
with rare genetic diseases.